Susquehanna International Group’s Eterna Therapeutics ERNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-1,234
Closed -$33.8K 12662
2025
Q3
$33.8K Buy
+1,234
New +$48.9K ﹤0.01% 11956
2025
Q1
Sell
-83
Closed -$9.16K 12724
2024
Q4
$9.16K Buy
+83
New +$22.5K ﹤0.01% 11987
2022
Q4
Sell
-5
Closed -$8K 12733
2022
Q3
$8K Sell
5
-1
-17% -$3.45K ﹤0.01% 12818
2022
Q2
$22K Buy
+6
New +$43.1K ﹤0.01% 12340
2021
Q4
Sell
-2
Closed -$109K 13292
2021
Q3
$108K Sell
2
-11
-85% -$950K ﹤0.01% 12021
2021
Q2
$1.71M Buy
+13
New +$1.87M ﹤0.01% 6289
2020
Q2
Sell
-2
Closed -$50K 10300
2020
Q1
$50K Buy
2
+1
+100% +$30.4K ﹤0.01% 9684
2019
Q4
$41K Hold
1
﹤0.01% 9385
2019
Q3
$35K Hold
1
﹤0.01% 9863
2019
Q2
$82K Buy
+1
New +$52.4K ﹤0.01% 9688
2015
Q2
Hold
0
-$6K 10169
2015
Q1
Hold
0
9326

Other funds holding ERNA

Susquehanna International Group's ERNA Position: Q4 2025 in Review

Susquehanna International Group sold out of Eterna Therapeutics (ERNA) in Q4 2025, closing a stake of 1,234 shares — an estimated $33.8K sold.

Susquehanna International Group first reported a position in ERNA in Q2 2019 and held it in 10 quarters. The position peaked at $1.71M in Q2 2021. 11 funds tracked by Wall St. Rank hold ERNA as of Q4 2025.

  • Susquehanna International Group reported no remaining Eterna Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Susquehanna International Group sold 1,234 Eterna Therapeutics shares in Q4 2025, an estimated $33.8K.
  • Susquehanna International Group first reported a position in Eterna Therapeutics in Q2 2019 and held it in 10 quarters.
  • Susquehanna International Group's Eterna Therapeutics position peaked at $1.71M in Q2 2021.
  • 11 funds tracked by Wall St. Rank held Eterna Therapeutics as of Q4 2025.

Based on Susquehanna International Group's 13F filing for Q4 2025, filed 17 Feb 2026.